West Pharmaceutical Services, Inc. $WST Position Reduced by Seilern Investment Management Ltd

Key Points

• Seilern Investment Management cut its West Pharmaceutical Services stake by 38.8% in the second quarter, selling 87,791 shares and retaining 138,230 shares valued at approximately $49.6 million. Institutional investors collectively own 93.9% of WST.
• West Pharmaceutical Services reported quarterly EPS of $2.37 and revenue of $872.3 million, exceeding analyst estimates of $2.08 EPS and $840.0 million revenue. Revenue increased 13.8% year over year, and the company provided fiscal 2026 EPS guidance of $8.85–$9.05.
• Analysts maintain a generally positive view, with the stock carrying an average “Buy” rating and a $368.08 price target. The company also declared a quarterly dividend of $0.22, equivalent to an annualized $0.88 and a 0.2% yield.

Seilern Investment Management Ltd lessened its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) by 38.8% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 138,230 shares of the medical instruments supplier's stock after selling 87,791 shares during the quarter. West Pharmaceutical Services comprises approximately 6.3% of Seilern Investment Management Ltd's portfolio, making the stock its 7th biggest holding. Seilern Investment Management Ltd owned 0.20% of West Pharmaceutical Services worth $49,625,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of WST. Elyxium Wealth LLC bought a new stake in shares of West Pharmaceutical Services in the fourth quarter valued at approximately $25,000. CYBER HORNET ETFs LLC bought a new position in West Pharmaceutical Services in the 2nd quarter worth approximately $25,000. Cornerstone Planning Group LLC grew its stake in West Pharmaceutical Services by 90.9% in the 1st quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier's stock valued at $26,000 after buying an additional 50 shares in the last quarter. Bayban bought a new stake in West Pharmaceutical Services during the 4th quarter valued at $27,000. Finally, Private Trust Co. NA raised its holdings in West Pharmaceutical Services by 156.4% during the 4th quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier's stock valued at $28,000 after acquiring an additional 61 shares during the period. Hedge funds and other institutional investors own 93.90% of the company's stock.

West Pharmaceutical Services Stock Up 1.4%

WST opened at $353.61 on Friday. The firm has a market capitalization of $24.89 billion, a P/E ratio of 45.28, a price-to-earnings-growth ratio of 2.47 and a beta of 1.15. West Pharmaceutical Services, Inc. has a one year low of $223.83 and a one year high of $386.00. The company has a fifty day moving average price of $342.97 and a 200-day moving average price of $292.25. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.82 and a quick ratio of 2.12.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.08 by $0.29. The company had revenue of $872.30 million for the quarter, compared to the consensus estimate of $839.98 million. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The firm's revenue was up 13.8% compared to the same quarter last year. During the same quarter last year, the business posted $1.84 earnings per share. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Equities research analysts expect that West Pharmaceutical Services, Inc. will post 8.94 earnings per share for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were issued a $0.22 dividend. The ex-dividend date of this dividend was Wednesday, July 29th. This represents a $0.88 annualized dividend and a dividend yield of 0.2%. West Pharmaceutical Services's dividend payout ratio (DPR) is presently 11.27%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Weiss Ratings reaffirmed a "hold (c)" rating on shares of West Pharmaceutical Services in a report on Friday, July 24th. Zacks Research raised West Pharmaceutical Services from a "hold" rating to a "strong-buy" rating in a report on Wednesday, May 13th. BNP Paribas Exane began coverage on West Pharmaceutical Services in a report on Monday, July 13th. They set an "outperform" rating and a $447.00 target price for the company. Evercore reiterated an "outperform" rating and set a $425.00 price target on shares of West Pharmaceutical Services in a research report on Monday, July 27th. Finally, Stephens reissued an "overweight" rating and issued a $360.00 price target on shares of West Pharmaceutical Services in a report on Tuesday, June 2nd. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Buy" and an average price target of $368.08.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source